[Correspondence] Regulatory asymmetry in Alzheimer's disease care

We welcome the European Commission's recent approval of lecanemab for the treatment of Alzheimer's disease.1 This decision allows the shift already underway in other countries to finally take place across Europe: a move from syndromal diagnosis at the dementia stage to biologically confirmed diagnosis earlier in the disease course. This transition will benefit not only the relatively small proportion of individuals who receive disease-modifying therapies, but also the much larger group of individuals with cognitive impairment, whether due to Alzheimer's disease or other causes.